论文部分内容阅读
目的为了研究食管鳞状细胞癌ＤＮＡ倍体异质性及其临床病理学意义，采用多点取材和流式细胞技术对８０例食管鳞状细胞癌标本的ＤＮＡ倍体进行了研究。方法每个标本从３个不同部位取材，８０例标本共取２４０个流式检测样品。采用ＦＡＣＳ－４２０型流式细胞仪（ＢｅｃｔｏｎＤｉｃｋｉｎｓｏｎＣｏ．ＳａｎＪｏｓｅ，ＣＡ）进行分析。校定仪器ＣＶ值为３％～５％。每个样品测量１０，０００～２０，０００个细胞。根据ＤＮＡ指数（ＤＮＡｉｎｄｅｘ，ＤＩ）确定倍体类型，ＤＩ＝１±０．１时为２倍体（２Ｃ）；０．９＜ＤＩ＞１．１时为异倍体（ａｎｅｕｐｌｏｉｄｙ，ＡＮ）。当一个标本的３个检测样品的Ｇ０／Ｇ１峰相互不同或３个峰的ＤＩ值相差大于２ＣＤＩ值的１０％时，该肿瘤被称为倍体异质性肿瘤（ｐｌｏｉｄｈｅｔｅｒｏｇｅｎｏｕｓｔｕｍｏｒ，ＰＨＴ），如果一个标本的３个样品的ＤＮＡ倍体类型相互一致，则称为非倍体异质性肿瘤（ｎｏｎ－ＰＨＴ，Ｎ－ＰＨＴ）。结果ＤＮＡ指数范围为０．７７～１．７４，ＤＮＡＡＮ检出率为８８．８％（７１／８０）。共检出ＰＨＴ３８例（４７．５％，３８／８０）。倍体异质性与肿瘤的侵润、转移和患者的预后有关，与肿瘤的大小及组织学分级无关。结?
Objective To study the DNA ploidy heterogeneity and clinicopathological significance of esophageal squamous cell carcinoma (ESCC), DNA ploidy of 80 esophageal squamous cell carcinoma specimens was studied by multi-point sampling and flow cytometry. Methods Each specimen was taken from 3 different sites, and 80 samples were collected for 240 flow test samples. Analysis was performed using a FACS-420 type flow cytometer (Becton Dickinson Co., San Jose, CA). Calibration equipment CV value of 3% to 5%. 10,000 to 20,000 cells were measured per sample. The type of ploidy was determined by DNA index (DI), which was diploid (2C) at DI = 1 ± 0.1 and aneuploidy (AN) at 0.9 . This tumor is called ploidheterogenoustumor (PHT) when the G0 / G1 peaks of three test samples in one specimen are different from each other or the DI values of the three peaks differ by more than 10% of 2 CDI values. If one The DNA samples of three samples were consistent with each other, which was called non-PHT (N-PHT). Results The DNA index ranged from 0.77 to 1.74. The DNAAN detection rate was 88.8% (71/80). PHT were detected in 38 cases (47.5%, 38/80). Ploidy heterogeneity and tumor invasion, metastasis and the prognosis of patients, and tumor size and histological grade unrelated. Knot?